- Home
- BCAB vs CCEL Comparison
BCAB vs CCEL Comparison
Compare BCAB & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- CCEL
- Stock Information
- Founded
- BCAB 2007
- CCEL 1989
- Country
- BCAB United States
- CCEL United States
- Employees
- BCAB N/A
- CCEL N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- CCEL Managed Health Care
- Sector
- BCAB Health Care
- CCEL Health Care
- Exchange
- BCAB Nasdaq
- CCEL Nasdaq
- Market Cap
- BCAB 31.5M
- CCEL 34.8M
- IPO Year
- BCAB 2020
- CCEL 1997
- Fundamental
- Price
- BCAB $0.68
- CCEL $4.41
- Analyst Decision
- BCAB Hold
- CCEL Strong Buy
- Analyst Count
- BCAB 3
- CCEL 1
- Target Price
- BCAB $1.00
- CCEL $8.50
- AVG Volume (30 Days)
- BCAB 1.1M
- CCEL 25.6K
- Earning Date
- BCAB 11-06-2025
- CCEL 10-14-2025
- Dividend Yield
- BCAB N/A
- CCEL 13.41%
- EPS Growth
- BCAB N/A
- CCEL N/A
- EPS
- BCAB N/A
- CCEL N/A
- Revenue
- BCAB $11,000,000.00
- CCEL $31,988,783.00
- Revenue This Year
- BCAB N/A
- CCEL $1.75
- Revenue Next Year
- BCAB N/A
- CCEL N/A
- P/E Ratio
- BCAB N/A
- CCEL N/A
- Revenue Growth
- BCAB N/A
- CCEL 1.10
- 52 Week Low
- BCAB $0.24
- CCEL $4.09
- 52 Week High
- BCAB $2.53
- CCEL $9.43
- Technical
- Relative Strength Index (RSI)
- BCAB 63.71
- CCEL 45.18
- Support Level
- BCAB $0.60
- CCEL $4.26
- Resistance Level
- BCAB $0.84
- CCEL $4.70
- Average True Range (ATR)
- BCAB 0.08
- CCEL 0.21
- MACD
- BCAB 0.02
- CCEL 0.00
- Stochastic Oscillator
- BCAB 62.14
- CCEL 33.87
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.